No Data
No Data
HOOKIPA Pharma to Cut Workforce by 80%, Shift Focus to KRAS Cancer Program
HOOKIPA Pharma Price Target Cut to $7.00/Share From $24.00 by JMP Securities
Hookipa Pharma Announces Workforce Reduction of 80%, Pause of Eseba-vec Program
JMP Securities Maintains HOOKIPA Pharma(HOOK.US) With Buy Rating, Cuts Target Price to $7
Strategic Shift and Partnership Potential Drive Buy Rating for HOOKIPA Pharma
Express News | HOOKIPA Pharma Inc: Will Focus Primarily on Progressing the Phase 1-Ready Hb-700 Program for the Treatment of Kras Mutant Cancers
No Data
No Data